NCT04080726View on ClinicalTrials.gov

Efficacy and Safety of HIP1601 Capsule

PHASE3CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

December 3, 2019

Study Completion Date

December 3, 2019

Conditions
Erosive Gastroesophageal Reflux Disease
Interventions
DRUG

HIP1601

Oral esomeprazole

DRUG

HGP1705

Oral Nexium Tab

DRUG

HIP1601 Placebo

Oral Placebo

DRUG

HGP1705 Placebo

Oral Placebo

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04080726 - Efficacy and Safety of HIP1601 Capsule | Biotech Hunter | Biotech Hunter